| Name | N-acetylcysteine amide |
| Description | N-Acetylcysteine amide is a thiol antioxidant and a neuroprotective agent with cell permeability and blood-brain barrier permeability. N-Acetylcysteine amide reduces ROS production. |
| Cell Research | To determine effectiveness of NACA and NAC in protection of H9c2 cells from DOX-induced toxicity, cells were treated with NACA or NAC at 0.75 mM for 2 h followed by exposure to freshly prepared cell culture medium with DOX in presence or absence of NACA or NAC at designated concentrations. The concentrations of DOX were 0.25 μM, 0.75 μM, 2 μM, 5 μM, 20 μM, and 100 μM. The exposure durations were 24 h, 48 h, or 48 h. Cells incubated with NACA or NAC alone were used as the control[1]. |
| Animal Research | rats were randomly divided into three groups (n=6-8 animals/group): N-acetylcysteine amide?loaded pump (18.5?mg/kg/hr) and a single 150 mg/kg bolus intraperitoneal (IP) injection of NACA given (30 min post-injury) ?N-acetylcysteine amide?(18.5 mg/kg/hr) loaded pump and a single 150 mg/kg bolus injection of N-acetylcysteine amide?given IP (30 min post-injury) ?Vehicle loaded pump and?single vehicle bolus injection given IP (30 min post-injury).?Following random distribution of all animals into one of the three previous groups, experimenters were blinded to treatment group.?The osmotic mini pumps were assembled and implanted immediately after injury and remained in the animals for 7 days[2] |
| In vitro | METHODS: Human esophageal cancer cells KYSE30 and KYSE150 were treated with LAT1-IN-1 (1-100 mM) for 3 days, and cell viability was measured by MTT assay.
RESULTS: LAT1-IN-1 treatment inhibited cell proliferation in a dose-dependent manner. [1]
METHODS: HTR8 SVneo, JEG-3 and JAR cells were treated with LAT1-IN-1 (0.1-4 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: LAT1 protein was significantly reduced after 24 h LAT1-IN-1 treatment, and LAT1-IN-1 could directly regulate the expression of LAT1. [2] |
| In vivo | METHODS: To assay antitumor activity in vivo, LAT1-IN-1 (200 mg/kg) was administered intravenously to BALB/c nude mice bearing KYSE150 tumors once daily for 14 days.
RESULTS: Daily treatment with LAT1-IN-1 for 14 consecutive days significantly delayed tumor growth. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (30.82 mM), Sonication is recommended.
H2O : 100 mg/mL (616.48 mM), Sonication is recommended.
DMSO : 245 mg/mL (1510.39 mM), Sonication is recommended.
|
| Keywords | ROS | ReactiveOxygenSpecies | Reactive Oxygen Species | N-Acetylcysteine amide | Nacetylcysteine amide | N acetylcysteine amide | Inhibitor | inhibit |
| Inhibitors Related | Ethoxyquin | Kaolin | Allopurinol | Cysteamine hydrochloride | Ethyl linoleate | Magnesium acetate tetrahydrate | Inosine | L-Cystine | Copper Sulfate Pentahydrate | Dimethyl itaconate | L-Ascorbic acid sodium salt | Dimethyl phthalate |
| Related Compound Libraries | Cuproptosis Compound Library | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library |
United States
